CurrentEndo
Get Weekly

CurrentEndo coverage · page 30 of 55

Diabetes, Obesity and Metabolism

Briefs 1,161–1,200 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    FRONTIER : FReeStyle Libre system use in Ontario among people with diabetes in the IC / ES database—Evidence from real‐world practice: Patients on basal insulin, glucagon‐like peptide 1 receptor agonist or oral therapies

    Cohort studyTechnology

  2. Diabetes Obes Metab

    Global, regional and country‐specific burden of chronic kidney disease due to type 1 diabetes mellitus: A systematic analysis of the 2021 global disease burden study

    Cohort studyT1D

  3. Diabetes Obes Metab

    Obesity‐related early structural alterations in the retina detected by optical coherence tomography

    Cross-sectional studyObesity

  4. Diabetes Obes Metab

    Impact of weight loss on obesity‐related complications and direct healthcare costs in Japan: A modelling study

    Research articleObesity

  5. Diabetes Obes Metab

    Comparing clinical outcomes of adults with obesity receiving tirzepatide versus bariatric metabolic surgery: A multi‐institutional propensity score‐matched study

    Cohort studyObesity

  6. Diabetes Obes Metab

    Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study

    Cohort studyObesity

  7. Diabetes Obes Metab

    Efficacy and safety of continuous glucose monitoring on glycaemic control in patients with chronic pancreatitis and insulin‐treated diabetes: A randomised, open‐label, crossover trial

    Randomized controlled trialTechnology

  8. Diabetes Obes Metab

    Clinical and biochemical profile of individuals with renal glucosuria: A matched cohort study

    Cohort studyT2D & other

  9. Diabetes Obes Metab

    Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea

    Cohort studyObesity

  10. Diabetes Obes Metab

    Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli‐ SWITCH study

    Research articleT2D & other

  11. Diabetes Obes Metab

    Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5

    Secondary analysisT2D & other

  12. Diabetes Obes Metab

    Use of semaglutide and risk of non‐arteritic anterior ischemic optic neuropathy: A Danish–Norwegian cohort study

    Cohort studyT2D & other

  13. Diabetes Obes Metab

    Discordance between serum cholesterol concentration and atherogenic lipoprotein particle number in people with metabolic disease: A systematic review

    Meta-analysisT2D & other

  14. Diabetes Obes Metab

    Kidney outcomes with SGLT2 inhibitors in patients with diabetes and an insulin‐deficient phenotype: A real world analysis

    Cohort studyComplications

  15. Diabetes Obes Metab

    Real‐world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database

    Cohort studyObesity

  16. Diabetes Obes Metab

    Association of BMI with mortality and health‐related quality of life among 4.4 million adults: Evidence from a nationwide, population‐based, prospective cohort study

    Cohort studyObesity

  17. Diabetes Obes Metab

    Associations of intra‐pancreatic fat deposition with triglyceride‐rich lipoproteins and lipoprotein lipase

    Cross-sectional studyLipids & liver

  18. Diabetes Obes Metab

    Effect of dapagliflozin on blood and breath ketones during supervised insulin withdrawal in adults with type 1 diabetes: A randomized crossover trial

    Randomized controlled trialT1D

  19. Diabetes Obes Metab

    Is serum 25‐hydroxyvitamin D deficiency a risk factor for the incidence of slow gait speed in older individuals? Evidence from the English longitudinal study of ageing

    Cohort studyBone & mineral

  20. Diabetes Obes Metab

    Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study

    Cross-sectional studyT1D

  21. Diabetes Obes Metab

    Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme

    Secondary analysisT2D & other

  22. Diabetes Obes Metab

    Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial

    Secondary analysisObesity

  23. Diabetes Obes Metab

    Identifying individuals at risk for weight gain using machine learning in electronic medical records from the United States

    Diagnostic or prognostic studyObesity

  24. Diabetes Obes Metab

    Impact of healthy lifestyles on the risk of metabolic dysfunction‐associated steatotic liver disease among adults with comorbid hypertension and diabetes: Novel insight from a largely middle‐aged and elderly cohort in South China

    Cohort studyLipids & liver

  25. Diabetes Obes Metab

    Data‐driven discovery of midlife cardiometabolic profile associated with incident early‐onset and late‐onset dementia

    Cohort study

  26. Diabetes Obes Metab

    Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real‐world retrospective study

    Cohort studyT2D & other

  27. Diabetes Obes Metab

    Effect of alirocumab on postprandial hyperlipidaemia in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, cross‐over trial

    Randomized controlled trialT2D & other

  28. Diabetes Obes Metab

    Effects of insulin‐induced hypoglycaemia on cardiac function in people with type 1 and type 2 diabetes and people without diabetes

    Mechanistic studyT2D & other

  29. Diabetes Obes Metab

    Insulin resistance in adipose tissue and fatty liver, but not fat mass, are involved in worsening glycaemic status: The Hiroshima study on glucose metabolism and cardiovascular diseases

    Cohort studyT2D & other

  30. Diabetes Obes Metab

    Workplace‐based continuous glucose monitoring with structured education for pre‐diabetes and type 2 diabetes: A prospective community cohort study

    Cohort studyT2D & other

  31. Diabetes Obes Metab

    Genetic evidence for the effects of glucokinase activation on frailty‐related outcomes: A Mendelian randomisation study

    Research articleT2D & other

  32. Diabetes Obes Metab

    Joint association of remnant cholesterol and lipoprotein‐associated phospholipase A2 with composite adverse events: A 12‐year follow‐up study from Asymptomatic Polyvascular Abnormalities Community study

    Cohort studyLipids & liver

  33. Diabetes Obes Metab

    Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment

    Cohort studyObesity

  34. Diabetes Obes Metab

    A systematic literature review on the burden of diabetic ketoacidosis in type 2 diabetes mellitus

    Research articleT2D & other

  35. Diabetes Obes Metab

    The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects

    Randomized controlled trialT2D & other

  36. Diabetes Obes Metab

    Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States

    Cross-sectional studyT1D

  37. Diabetes Obes Metab

    Anthropometric metabolic subtypes and health outcomes: A data‐driven cluster analysis

    Cohort studyObesity

  38. Diabetes Obes Metab

    Carnitine supplementation improves insulin sensitivity and skeletal muscle acetylcarnitine formation in patients with type 2 diabetes

    Research articleT2D & other

  39. Diabetes Obes Metab

    Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020

    Cross-sectional studyComplications

  40. Diabetes Obes Metab

    iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan ‐O‐ AP and LixiLan ‐L‐ CN studies

    Secondary analysisT2D & other

All 2,200 Briefs in ExploreShowing Briefs 1,161–1,200 of 2,200, newest first